Replies to post #33314 on Biotech Values

[DewDiligence]

>that is great news for NFLD investors, as it would potentially slam the door shut for competitors like BPUR<

I’m not sure I would count BPUR as a competitor if you’re thinking in terms of commercial products during the next 5 years. If they are not out of business entirely, BPUR will probably still be running clinical trials well into the next decade.